Mankind Pharma Share Price
Sector:
You have to be logged in to add this to Watchlist.
Login or Register
2555.35 +2.75 (0.11%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2534.8
Today’s High
2598.95
52 Week Low
1820.15
52 Week High
2882.75
2554.00 -4.65 (-0.18%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2532.1
Today’s High
2580
52 Week Low
1821
52 Week High
2874
Key Metrics
- Market Cap (In Cr) 102515.4
- Beta -
- Div. Yield (%) 0
- P/B 10.95
- TTM P/E 47.75
- Peg Ratio 3.3
- Sector P/E 32.87
- D/E 0.05
- Open Price 2598.95
- Prev Close 2552.6
Mankind Pharma Analysis
Price Analysis
-
1 Week-2.42%
-
3 Months10.31%
-
6 Month21.84%
-
YTD29.06%
-
1 Year32.24%
Risk Meter
- 30% Low risk
- 30% Moderate risk
- 30% Balanced Risk
- 30% High risk
- 30% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 5
- 5
- 4
- 2
- Buy
- 5
- 5
- 5
- 5
- Hold
- 3
- 3
- 3
- 4
- Sell
- 1
- 1
- 1
- 1
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 14
- 14
- 13
- 12
Mankind Pharma News
This multi-billion dollar opportunity could be a game changer for Wockhardt
8 min read . 21 Nov 2024Mankind Pharma pledges 39.68% stake in Bharat Serums to secure ₹5,000 crore NCDs
1 min read . 15 Nov 2024Home remedy: Indian pharma bets on domestic brands to fight US generics slowdown
4 min read . 08 Nov 2024Diwali 2024 Picks: JSW Energy to CDSL — top six stocks to buy in Samvat 2081
6 min read . 27 Oct 2024Mankind Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 10334.77
- Selling/ General/ Admin Expenses Total
- 3306.91
- Depreciation/ Amortization
- 398.2
- Other Operating Expenses Total
- 1084.43
- Total Operating Expense
- 8195.7
- Operating Income
- 2139.08
- Net Income Before Taxes
- 2399.36
- Net Income
- 1912.9
- Diluted Normalized EPS
- 47.66
- Period
- 2024
- Total Assets
- 11963.25
- Total Liabilities
- 2600.17
- Total Equity
- 9363.09
- Tangible Book Valueper Share Common Eq
- 191.72
- Period
- 2024
- Cashfrom Operating Activities
- 2152.44
- Cashfrom Investing Activities
- -2081.69
- Cashfrom Financing Activities
- 5.27
- Net Changein Cash
- 77.19
- Period
- 2023
- Total Revenue
- 8749.43
- Selling/ General/ Admin Expenses Total
- 3763.95
- Depreciation/ Amortization
- 325.86
- Total Operating Expense
- 7174.72
- Operating Income
- 1574.72
- Net Income Before Taxes
- 1671.24
- Net Income
- 1281.86
- Diluted Normalized EPS
- 32.06
- Period
- 2023
- Total Assets
- 9715.45
- Total Liabilities
- 2280.23
- Total Equity
- 7435.22
- Tangible Book Valueper Share Common Eq
- 141.21
- Period
- 2023
- Cashfrom Operating Activities
- 1813.3
- Cashfrom Investing Activities
- -1054.13
- Cashfrom Financing Activities
- -739.73
- Net Changein Cash
- 21.76
- Period
- 2022
- Total Revenue
- 7781.56
- Selling/ General/ Admin Expenses Total
- 3209.56
- Depreciation/ Amortization
- 166.56
- Total Operating Expense
- 5929.56
- Operating Income
- 1851.99
- Net Income Before Taxes
- 1974.6
- Net Income
- 1433.48
- Diluted Normalized EPS
- 35.36
- Period
- 2022
- Total Assets
- 9147.74
- Total Liabilities
- 2992.51
- Total Equity
- 6155.23
- Tangible Book Valueper Share Common Eq
- 106.36
- Period
- 2022
- Cashfrom Operating Activities
- 919.78
- Cashfrom Investing Activities
- -1369.14
- Cashfrom Financing Activities
- 604.62
- Net Changein Cash
- 155.73
- Period
- 2021
- Total Revenue
- 6214.43
- Selling/ General/ Admin Expenses Total
- 2583.6
- Depreciation/ Amortization
- 118.92
- Other Operating Expenses Total
- 50.58
- Total Operating Expense
- 4682.26
- Operating Income
- 1532.18
- Net Income Before Taxes
- 1691.61
- Net Income
- 1265.43
- Diluted Normalized EPS
- 31.98
- Period
- 2021
- Total Assets
- 6372.63
- Total Liabilities
- 1650.63
- Total Equity
- 4722
- Tangible Book Valueper Share Common Eq
- 116.9
- Period
- 2021
- Cashfrom Operating Activities
- 1137.24
- Cashfrom Investing Activities
- -1222.21
- Cashfrom Financing Activities
- -7.81
- Net Changein Cash
- -92.4
- Period
- 2020
- Total Revenue
- 5865.23
- Selling/ General/ Admin Expenses Total
- 2294.37
- Depreciation/ Amortization
- 99.05
- Other Operating Expenses Total
- 40.14
- Total Operating Expense
- 4518.47
- Operating Income
- 1346.77
- Net Income Before Taxes
- 1437.74
- Net Income
- 1030.42
- Diluted Normalized EPS
- 27.27
- Period
- 2020
- Total Assets
- 5073.28
- Total Liabilities
- 1587.98
- Total Equity
- 3485.31
- Tangible Book Valueper Share Common Eq
- 85.85
- Period
- 2020
- Cashfrom Operating Activities
- 1069.7
- Cashfrom Investing Activities
- -439.16
- Cashfrom Financing Activities
- -530.74
- Net Changein Cash
- 103.42
- Period
- 2024-09-30
- Total Revenue
- 3076.51
- Selling/ General/ Admin Expenses Total
- 646.43
- Depreciation/ Amortization
- 105.62
- Other Operating Expenses Total
- 705.15
- Total Operating Expense
- 2332.09
- Operating Income
- 744.42
- Net Income Before Taxes
- 849.32
- Net Income
- 653.47
- Diluted Normalized EPS
- 16.28
- Period
- 2024-09-30
- Total Assets
- 13982.25
- Total Liabilities
- 3417.49
- Total Equity
- 10564.76
- Tangible Book Valueper Share Common Eq
- 222.76
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 1139.33
- Cashfrom Investing Activities
- -1035.42
- Cashfrom Financing Activities
- 240.51
- Net Changein Cash
- 344.62
- Period
- 2024-06-30
- Total Revenue
- 2893.42
- Selling/ General/ Admin Expenses Total
- 633.78
- Depreciation/ Amortization
- 107.74
- Other Operating Expenses Total
- 765.35
- Total Operating Expense
- 2319.4
- Operating Income
- 574.02
- Net Income Before Taxes
- 667.62
- Net Income
- 536.49
- Diluted Normalized EPS
- 13.37
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2441.1
- Selling/ General/ Admin Expenses Total
- 599.89
- Depreciation/ Amortization
- 104.69
- Other Operating Expenses Total
- 512.81
- Total Operating Expense
- 1954.68
- Operating Income
- 486.42
- Net Income Before Taxes
- 571.58
- Net Income
- 471.24
- Diluted Normalized EPS
- 11.74
- Period
- 2024-03-31
- Total Assets
- 11963.25
- Total Liabilities
- 2600.17
- Total Equity
- 9363.09
- Tangible Book Valueper Share Common Eq
- 191.72
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 2152.44
- Cashfrom Investing Activities
- -2081.69
- Cashfrom Financing Activities
- 5.27
- Net Changein Cash
- 77.19
- Period
- 2023-12-31
- Total Revenue
- 2606.96
- Selling/ General/ Admin Expenses Total
- 568.35
- Depreciation/ Amortization
- 109.73
- Other Operating Expenses Total
- 604.51
- Total Operating Expense
- 2110.18
- Operating Income
- 496.78
- Net Income Before Taxes
- 562.33
- Net Income
- 453.76
- Diluted Normalized EPS
- 11.31
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 2708.1
- Selling/ General/ Admin Expenses Total
- 571.96
- Depreciation/ Amortization
- 96.48
- Other Operating Expenses Total
- 628.63
- Total Operating Expense
- 2121.94
- Operating Income
- 586.16
- Net Income Before Taxes
- 640.99
- Net Income
- 501.03
- Diluted Normalized EPS
- 12.49
- Period
- 2023-09-30
- Total Assets
- 11098.32
- Total Liabilities
- 2669.87
- Total Equity
- 8428.45
- Tangible Book Valueper Share Common Eq
- 167.5
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 968.91
- Cashfrom Investing Activities
- -1015.03
- Cashfrom Financing Activities
- -6.79
- Net Changein Cash
- -51.33
- Period
- 2023-06-30
- Total Revenue
- 2578.62
- Selling/ General/ Admin Expenses Total
- 552.91
- Depreciation/ Amortization
- 87.35
- Other Operating Expenses Total
- 550.93
- Total Operating Expense
- 2011.16
- Operating Income
- 567.46
- Net Income Before Taxes
- 624.47
- Net Income
- 486.87
- Diluted Normalized EPS
- 12.15
- Period
- 2023-06-30
- Period
- 2023-06-30
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Mankind Pharma Technical
Moving Average
SMA
- 5 Day2586.65
- 10 Day2642.92
- 20 Day2608.33
- 50 Day2595.4
- 100 Day2388.62
- 300 Day2296.83
Mankind Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Jio Financial Services
- 313.85
- -0.25
- -0.08
- 394.7
- 215.1
- 199397.82
- Mankind Pharma
- 2555.35
- 2.75
- 0.11
- 2882.75
- 1820.15
- 102364.37
No Network
Server Issue
Internet Not Available
×
×
Get alerts on WhatsApp
Gift an article Set Preferences My Reads Watchlist Feedback Redeem a Gift Card Logout